Trading-news Biopharma Stock List Update: Arry, Fold, Jav, Vnda, Ngsx
 

Biopharma stock list performances, we signal:

ARRY (NASDAQ) up 18% to 3,8 usd

FOLD(NASDAQ) up 5% above 11 usd

VNDA(NASDAQ) up 5% at 14 usd

We are selling NGSX (NASDAQ) at 8,2 usd with 30% gain

JAV (AMEX) up 10% to 1,8 usd

SLXP (NASDAQ) at 12 usd, ACAD (NASDAQ) at 2,5 usd

We are adding ONXX (NASDAQ) after strong Nexavar clinical data

We are rebuying NPSP (NASDAQ) at 4,7 usd due the strong consensus

TICKER                       BUY AREA      QUOTE NOW     POSITION            DRIVER

NPSP (NASDAQ)      USD 4,7                  4,66                 LT                STRONG CONSENSUS

ONXX(NASDAQ)       USD 35,9              35                   LT                      NEXAVAR

IDIX (NASDAQ)        USD  4,44            4,2 SOLD(-5%)

SNTS (NASDAQ)     USD   2,81            3   LONG TERM    FDA REVIEW Zegerid BY DECEMBER

BFRM (NASDAQ)        USD   2,85           2            LONG TERM OVERSOLD CONDITIONS

OCLS (NASDAQ) USD 2,85     2,75          LONG TERM    MORE UPSIDE

TRGT (NASDAQ) USD 5,5          8,7 SOLD(+60%) 

OREX (NASDAQ) USD 5,35     6,45 SOLD(+20%)  

FOLD (NASADQ) USD 10           11,2  LONG TERM     PLICERA, AMIGAL STRONG  CONSENSUS

SOMX (NASDAQ) USD 1,10       1,38   SOLD (+25%)    

DDSS (NASDAQ)  USD 2,65    2    HOLD  TRAZODONE manifacturing issue 7/24/09

XNPT (NASDAQ)  USD 21,85      20,8    LONG TERM    XP19986  POSITIVE TRIAL 6/30/09

VNDA (NASDAQ) 12,1                 14        REBUYING      FANAT APPROVED 5/6/09

CYTR (NASDAQ)   USD 1,02      1,21        LONG TERM    STRONG  CONSENSUS

JAZZ (NASDAQ)    USD 4,95     4,3    LONG TERM         STRONG CONSENSUS

PARD (NASDAQ)    USD 5          5,9      PROFIT TAKING(+18%)     

PARD (NASDAQ) USD 6,6 rebought 7/2    7,2  LONG TERM       STRONG CONSENSUS

INCY (NASDAQ) USD 3,5         4,4    LONG TERM            STRONG CONSENSUS

ISTA (NASDAQ) USD 4,1      4,9   LONG TERM          BEPREVE FDA  PDUFA  9/12/09

JAV (AMEX)      USD 1,3          1,8       LONG TERM         STRONG CONSENSUS

SLXP (NASDAQ) USD 9,9       12 LONG TERM  STRONG CONSENSUS FDA  PDUFA 9/9/09

MAPP (NASDAQ) USD 11,3       10  REBUYING LONG TERM STRONG CONSENSUS 

ARYX (NASDAQ) USD            4,5       SOLD 2,5 (-45%)

ARRY (NASDAQ) USD 3,1      3,8    LONG TERM           CLINICAL TRIAL 7/8/09

GTXI (NASDAQ)   USD 9,5      9     LONG TERM         FDA PDUFA 10/30/09

UTHR (NASDAQ) USD 84         84,5 LONG TERM        FDA PDUFA 7/30/09

NGSX (NASDAQ) USD 6,4      8,2 SOLD(+30%)

VICL (NASDAQ)  USD 3             2,85    LONG TERM      SWINE FLU

STAA (NASDAQ)  USD 3,3        2,5 LONG TERM   FDA CLEARENCE FOR Epiphany(TM)

ALTH (NASDAQ)  7,9               7,5   LONG TERM          FDA PDUFA 9/24/09

AMAG (NASDAQ) 52,8        50  LONG TERM        FDA APPROVES FERAHEME 6/30/09

XOMA (NASDAQ) 1,2    0,75  LONG TERM  OVERSOLD

HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                

HEB (AMEX) was rebought after 100% gain (see old posts)

MRNA (NASDAQ)  3,3            1,4      LONG TERM      OVERSOLD

RIGL (NASDAQ) USD 10           13,5     LONG TERM     STRONG CONSENSUS

MITI (NASDAQ) USD 6              5,15       LONG TERM      OVERSOLD

MNKD (NASDAQ) USD 8,3         7,95    SOLD(-4%)    

SVNT (NASDAQ) USD 7,10        13       SOLD(+90%)

NPSP (NASDAQ) 3,1 USD        4,75     SOLD(+50%)

SCLN (NASDAQ) 2,25 USD        2,7     SOLD (+20%)  LONG TERM ZADAXIN SALES

MAPP (NASDAQ) 8 USD  (posts from 5/26)  PROFIT TAKED(+45%)   LEVADEX

VNDA (NASDAQ) 8 USD (see old post 5/8)  PROFIT TAKED(+80%)     FANAT

CLDA (NASDAQ) 15,7 USD       10,3  LONG TERM   OVERSOLD

CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%)

ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%)

MEDX (NASDAQ) 7,5 USD   8,7  PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS

MNTA (NASDAQ) 8,9 USD      11,1   LONG TERM   STRONG CONSENSUS

ACAD (NASDAQ) 2,6 USD     2,42       LONG TERM  CLINICAL DATA  3 Q.

ACOR (NASDAQ) 24 USD   24  LONG TERM FAMPRIDINE-SR, FDA PDUFA 10/22/09

BDSI (NASDAQ)                           PROFIT TAKED 6,3  (+18%)  

BDSI (NASDAQ)  6,6 rebought   5,4      SHORT TERM    ONSOLIS APPROVED BY FDA

DNDN (NASDAQ)  22 USD (see old post 4/27) 23,2  LONG TERM  PROVENGE

SPPI (NASDAQ)  4 USD (see ols post 5/12)    6/12  PROFIT TAKING (+35%)

SPPI (NASDAQ)  5,85 USD         7,4     PROFIT TAKING(+28%) 

SPPI (NASDAQ)  6,5 USD rebought 7/2  6,45  LT  ZEVALIN FDA PDUFA  09/07/09

FUSILEV PDUFA 08/10/09